| Symbol | TSX : AMB |
|---|---|
| Last trade | 0.15 |
| Volume | 120,450 |
| As of | 2008-08-19 15:59 EST |
| Note: Quotes are delayed. For informational purposes only. |
|
Investors
Executing the Strategy
Ambrilia’s strategy is to capitalize on its broad product portfolio and original expertise in virology. During the course of 2008, execution of the strategy aims to monetize the non-virology assets through third parties agreements, in turn strengthening the Company’s financial position to continue building its novel pipeline of antivirals.
Fact Sheet (PDF 816 Kb)
Corporate Presentation (PDF 1.07 Mb)
| 2008 Milestones: Summary |
|---|
| Divestment: Asset Sale or Licensing Partnership |
| Octreotide (C2L) |
| Goserelin |
| PCK3145 |
| NGR-Delivery Technology |
| PSP94 |
| H1 2008 |
| Octreotide (C2L): Advance clinical Phase III (achieved) |
| Goserelin: Complete formulation work (achieved) |
| H2 2008 |
| NGR-Delivery Technology : siRNA proof-of-concept in vivo (achieved) |
